Back to library
ImmuneSubcutaneous
Thymosin Alpha-1
Also known as: TA1 · Tα1 · Zadaxin
28-amino-acid thymic peptide that modulates innate and adaptive immunity. Enhances dendritic cell maturation, increases Th1 cytokines, and boosts cytotoxic T-cell and NK-cell activity. Approved in 35+ countries for hepatitis B/C and as adjuvant in sepsis.
At a glance
- Half-life
- 2 hours
- Common route
- Subcutaneous
- Typical dose range
- 750–1,600mcg
- Stability (reconstituted)
- 30days refrigerated
Best timing
Typically 2x weekly, or daily for 5 days during acute illness. Many users cycle 4–8 weeks on, then break.
Contraindications
- Active organ transplant on immunosuppression (immune activation can trigger rejection)
- Pregnancy
- Severe autoimmune disease (relative contraindication)
Watch symptoms
- Injection site irritation
- Mild flu-like feeling early in protocol (immune activation)
- Joint achiness
- Fatigue first few days
- Possible autoimmune flare in susceptible individuals
Citations